Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow

Annals of Hematology

Volumn 93, Issue 1, 2014, Pages 65-69

  Neukirchen, Judith ^a   Platzbecker, Uwe ^b   Sockel, Katja ^b   Tsamaloukas, Antonis ^c   Haas, Rainer ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Private Practice   (Germany)

Author keywords

Alemtuzumab; ATG; Immunosuppressive therapy; MDS

Indexed keywords

ALEMTUZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; FEMALE; HUMAN; LONG TERM SURVIVAL; MALE; MIDDLE AGED; PERSONAL EXPERIENCE; PRIORITY JOURNAL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84891848153     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1859-1     Document Type: Article

References (20)

1. Olnes JO, Sloand EM (2011) Targeting immune dysregulation in myelodysplastic syndromes. JAMA 305:814-819
2. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC (2003) A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 120:679-684 (Pubitemid 36255870)
3. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, Schrezenmeier H, Novotny J, Anders O, Eimermacher H, Verbeek W, Kreipe HH, Heimpel H, Aul C, Ganser A (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460-465 (Pubitemid 38425859)
4. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A (2011) Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care - SAKK 33/9. J Clin Oncol 29:303-309
5. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26:2505-2511
6. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ (2003) A simple method to predict response to immunosuppressive therapy in patients with meylodysplastic syndrome. Blood 102:3025-3027 (Pubitemid 37248879)
7. Bennet WM (1998) The nephrotoxicity of new and old immunosuppressive drugs. Ren Fail 20:687-690
8. Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, Wu CO, More K, Barrett AJ, Scheinberg P, Young NS (2010) Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 28:5166-5173
9. Demko S, Summer J, Keegan P, Pazdur R (2008) FDA drug approval summary: alemtuzumab as a single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 13:167-174 (Pubitemid 351342581)
10. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC (2007) Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26:3644-3653 (Pubitemid 46842714)
11. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, Lu J, Basu A, Barrett AJ, Young NS (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106:841-851 (Pubitemid 41076423)
12. Lim ZY, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A, Marsh J, Mufti GJ (2007) Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21:1436-41 (Pubitemid 46965284)
13. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425 (Pubitemid 44061337)
14. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA, British Committee for Standards in Haematology (2009) Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 147:43-70
15. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ (1997) Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99:699-705 (Pubitemid 27519877)
16. Scott BL, Ramakrishnan A, Fosdal M, Storer B, Becker P, Petersdorf S, Deeg HJ (2010) Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol 149:706-710
17. Nachtkamp K, Kündgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N, Haas R, Germing U (2009) Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33:1024-1028
18. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, Simonis T, Molldrem J, Young NS, Barrett AJ (2002) HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100:1570-1574 (Pubitemid 34925129)
19. Ley TJ, Ding L, Walter MJ et al (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433
20. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Graubert TA (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:1153-1158